Potter Clarkson is delighted to be featured in the 2023 edition of the World Trademark Review (WTR) 1000 - the definitive resource for those seeking world-class trade mark legal expertise.
Potter Clarkson has capped a very successful year with the announcement of 13 promotions.
In this white paper we discuss why creating a strong IP strategy is essential to a business’ success and examine the components that should be considered and included.
The EPO’s Enlarged Board of Appeal has attempted to clarify the law concerning the doctrine of ‘plausibility’ and the use of post-filed data to support inventive step. The questions answered are of particular relevance to those in the life science sector.
The stage is set for another referral to the Court of Justice of the EU on the eligibility criteria for Supplementary Protection Certificates for “combination products” - those comprising two or more active ingredients.
Anna has just joined Potter Clarkson this summer and Potter Clarkson’s Tom Harding sat down to chat with her at the Nordic Life Science Days conference.
In this article by Sarah Speight, Sheena Linehan has been quoted alongside the director of IP at the World Trade Organisation and the global patent head of an international law firm.
Dave Holt, senior associate and licensing specialist, comments on the recent Court of Appeal decision Neurim v Generics [2022] EWCA Civ 359 and its implications on licensing Unitary Patents.
According to many, the anticipated arrival of Humira biosimilars in the US next year has pushed AbbVie's drug to the precipice of the pharma industry’s biggest-ever patent cliff.
Patent Offices around the world are busy preparing for the ‘big bang’ date of 1 July 2022 on which the new international standard for providing sequence listings (Standard ST.26) will come into force, simultaneously replacing existing Standard ST.25. Applicants and their representatives will need to be aware of the change and its consequences to avoid difficulties.
A recent case involving Bristol Myers Squibb, which resulted in the revocation of a patent filed by the pharmaceutical giant, serves as a salutary warning on the risks of failing to include detailed supporting data when an application is first filed.
The Court of Justice of the EU (CJEU) has once again been asked to explain the eligibility criteria for SPCs for “combination products” - those comprising two or more active ingredients.
The European Commission has opened a call for evidence on proposals for a single procedure for the granting of SPCs across the European Union.
The Henry Royce Institute and the World Economic Forum have drawn attention to the need for us to accelerate the development of advanced materials, including 2D materials.
The European Commission has announced a new initiative for a single procedure for the granting of SPCs across the European Union.